![](https://monteverdelaw.com/wp-content/uploads/case-logo/point-biopharma-global-inc.jpg)
POINT Biopharma Global, Inc. (Nasdaq: PNT), relating to its proposed sale to Eli Lilly. Under the terms of the agreement, PNT shareholders will receive $12.50 in cash per share they own.
POINT Biopharma Global, Inc. (Nasdaq: PNT), relating to its proposed sale to Eli Lilly. Under the terms of the agreement, PNT shareholders will receive $12.50 in cash per share they own.